Corvus Pharmaceuticals (CRVS) Insider Trading & Ownership $5.01 +0.28 (+5.92%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Corvus Pharmaceuticals (NASDAQ:CRVS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage31.30%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$1.03 MNumber OfInsiders Selling(Last 12 Months)0 Get CRVS Insider Trade Alerts Want to know when executives and insiders are buying or selling Corvus Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CRVS Insider Buying and Selling by Quarter Corvus Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/6/2024Richard A Md MillerCEOBuy577,634$1.73$999,306.82 5/6/2024William Benton JonesInsiderBuy20,000$1.73$34,600.00 (Data available from 1/1/2013 forward) CRVS Insider Trading Activity - Frequently Asked Questions Who is on Corvus Pharmaceuticals's Insider Roster? The list of insiders at Corvus Pharmaceuticals includes Leiv Lea, Linda Grais, Richard A Md Miller, and William Benton Jones. Learn more on insiders at CRVS. What percentage of Corvus Pharmaceuticals stock is owned by insiders? 31.30% of Corvus Pharmaceuticals stock is owned by insiders. Learn more on CRVS's insider holdings. Which Corvus Pharmaceuticals insiders have been buying company stock? The following insiders have purchased CRVS shares in the last 24 months: Linda Grais ($24,500.00), Richard A Md Miller ($999,306.82), and William Benton Jones ($34,600.00). How much insider buying is happening at Corvus Pharmaceuticals? Insiders have purchased a total of 607,634 CRVS shares in the last 24 months for a total of $1,058,406.82 bought. Corvus Pharmaceuticals Key ExecutivesDr. Richard A. Miller M.D. (Age 73)Co-Founder, President, CEO & Chairman of the Board Compensation: $116.31kDr. Peter A. Thompson FACP (Age 64)M.D., Co-Founder & Independent Director Compensation: $47kMr. Leiv Lea (Age 70)Chief Financial Officer Compensation: $400.21kDr. William Benton Jones Ph.D. (Age 58)Senior Vice President of Pharmaceutical Development Compensation: $355.7kDr. James T. Rosenbaum M.D.Senior Vice President of ResearchMr. Jeffrey S. ArcaraChief Business Officer More Insider Trading Tools from MarketBeat Related Companies KNSA Insider Transactions MRVI Insider Transactions RCUS Insider Transactions OCUL Insider Transactions ARVN Insider Transactions PRAX Insider Transactions DAWN Insider Transactions ANIP Insider Transactions AUPH Insider Transactions SPRY Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (NASDAQ:CRVS) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
